Table 1.

Lipoprotein and fibrinogen concentrations during atorvastatin and fenofibrate therapy (n = 11).

	atorvastatin			fenofibrate
	before (mg/dL)	during (mg/dL)	change (%)	before (mg/dL)	during (mg/dL)	change (%)
Total cholesterol	260 ± 46	193 ± 45	-25***	270 ± 48	219 ± 26	-17***
Total triglycerides	313 ± 198	210 ± 63	-11	320 ± 190	162 ± 48	-42***
LDL-cholesterol	150 ± 39	108 ± 39	-28**	161 ± 48	142 ± 23	-7
large, buoyant	15.2 ± 7.1	10.8 ± 5.4	-27**	17.8 ± 9.4	14.2 ± 3.6	-10
intermediate dense	57.8 ± 25.2	42.8 ± 19.4	-22*	61.8 ± 29.0	75.9 ± 20.2	+31
small, dense	85.9 ± 13.4	57.8 ± 17.5	-23*	91.8 ± 17.8	61.9 ± 19.2	-32*
HDL-cholesterol	46.8 ± 9.4	51.1 ± 10.4	+15*	50.6 ± 12.6	55.1 ± 11.6	+14*
Fibrinogen	406 ± 41	400 ± 41	-1	411 ± 57	329 ± 32	-19**

a: *p < 0.05; **p < 0.01; ***p < 0.005. b: LDL subtypes refer to following density intervals: large buoyant LDL 1.020 – 1.029 g/mL, intermediate dense LDL 1.030 – 1.034 g/mL, small dense LDL 1.041–1.066 g/mL. c: The data from 10 out of 11 patients were published previously [16].